You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: KLEIN BUENDEL, INC. Topic: NCI
DESCRIPTION (provided by applicant): Over the past decade, an investigation of how family members talk through cancer on the telephone has resulted in the recent publication of a lengthy volume entitled A Natural History of Family Cancer: Interactional Resources for Managing Illness (NH). Based on the conversations analyzed for this volume, and related research on the psychosocial impacts and con ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: VIBRANT CORP Topic: DLA15C001
Vibrant Corporation and Sandia National Laboratories (SNL) propose to apply Process Compensated Resonance Testing (PCRT) to the DLA's need for an NDI method to detect counterfeit, nonconforming and improperly processed materiel. PCRT collects and analyzes the resonance frequencies of a component to detect structural defects, characterize material, analyze population variation, monitor manufacturin ...STTR Phase I 2016 Department of DefenseDefense Logistics Agency
SBC: Flocel Inc. Topic: NIMH
DESCRIPTION (provided by applicant): Increasing evidence indicates that systemic inflammation and the blood-brain barrier (BBB), which becomes the target of overreacting or misguided immune cells that determine BBB failure and immune extravasations into the brain parenchyma, are involved in the pathogenesis of neurological diseases such as meningitis, inflammation, Alzheimer's disease, and multipl ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
Development of a novel platform to enhance intracellular bioavailability of antisense morpholino oligomersSBC: NAJIT TECHNOLOGIES INC Topic: NIAID
DESCRIPTION provided by applicant Peptide conjugated phosphorodiamidate morpholino oligomers PPMO are single stranded nucleic acid analogs able to modulate gene expression through steric blocking of complementary RNA PPMO are composed of two components an antisense morpholino oligomer cargo covalently conjugated to a cell penetrating delivery peptide PPMO are completely nuclease resistant ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: NIAID
DESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Celetrix LLC Topic: NIAID
DESCRIPTION provided by applicant Transplantation of human or animal pluripotent stem cells PSCs or their derivatives to model animals constitutes an important preclinical system to model and investigate cell survival development and differentiation in vivo and to assess the safety and efficacy of transplantation based cell therapies Immunodeficient mice are dominantly used in biomedical ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: NEOGENE BIOSCIENCES, LLC Topic: NIA
DESCRIPTION (provided by applicant): The long term goal of this project is to develop and commercialize noninvasive equipment, called the sleep and respiratory track (SARTrak) system, for high throughput detection of sleep apnea in animals. The specific goal for the Phase I application is to design and evaluate a basic model of the SARTrak system with eight chambers (one chamber per animal), i.e. ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: Biotherapeutics, Inc. Topic: NIDDK
DESCRIPTION (provided by applicant): About 28.3 million Americans have type II diabetes (T2D) and over 40.1% of middle-aged adults have prediabetes, a condition characterized by impaired glucose tolerance and insulin resistance. Current antidiabetic medications are effective in improving insulin sensitivity, but their chronic administration has significant side effects suc as cardiovascular compli ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: TDA RESEARCH, INC. Topic: NIAID
Project Summary Abstract Development of Optimized Endectocide treated Bird Feed Formulations for West Nile Virus Control STTR Phase I Application PIs Brady Clapsaddle TDA Research Inc Dr Brian Foy Colorado State University West Nile Virus WNV is the leading cause of domestically acquired arboviral disease in the United States resulting in significant disease and death every year in both ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: H-CUBED Topic: NHLBI
DESCRIPTION provided by applicant Congenital diaphragmatic hernia CDH affects in newborns CDH is a disorder in which part of the diaphragm fails to form allowing abdominal organs to migrate into the chest resulting in lung hypoplasia underdevelopment in affected infants Although great strides have been made in the management of this disease significant morbidity and mortality p ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health